Cytek Biosciences, Inc.
NASDAQ:CTKB
5.06 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 193.015 | 164.036 | 127.95 | 92.839 | 57.883 |
| Cost of Revenue
| 83.589 | 63.062 | 48.806 | 41.129 | 29.209 |
| Gross Profit
| 109.426 | 100.974 | 79.144 | 51.71 | 28.674 |
| Gross Profit Ratio
| 0.567 | 0.616 | 0.619 | 0.557 | 0.495 |
| Reseach & Development Expenses
| 44.151 | 34.858 | 24.442 | 13.693 | 8.931 |
| General & Administrative Expenses
| 43.972 | 34.69 | 20.825 | 9.37 | 6.739 |
| Selling & Marketing Expenses
| 49.148 | 33.23 | 24.71 | 14.988 | 10.241 |
| SG&A
| 91.62 | 67.92 | 45.535 | 24.358 | 16.98 |
| Other Expenses
| 7.794 | 1.018 | -1.527 | 0.994 | 0.252 |
| Operating Expenses
| 135.771 | 102.778 | 69.977 | 38.051 | 25.911 |
| Operating Income
| -26.345 | -1.826 | 6.447 | 13.659 | 3.726 |
| Operating Income Ratio
| -0.136 | -0.011 | 0.05 | 0.147 | 0.064 |
| Total Other Income Expenses Net
| 10.636 | 3.086 | -0.499 | 0.771 | -20.02 |
| Income Before Tax
| -15.709 | 1.26 | 5.948 | 14.43 | -16.294 |
| Income Before Tax Ratio
| -0.081 | 0.008 | 0.046 | 0.155 | -0.281 |
| Income Tax Expense
| -3.561 | -1.224 | 1.505 | -4.981 | 0.533 |
| Net Income
| -12.148 | 2.576 | 4.417 | 19.411 | -16.827 |
| Net Income Ratio
| -0.063 | 0.016 | 0.035 | 0.209 | -0.291 |
| EPS
| -0.09 | 0.019 | 0.033 | 0.024 | -0.13 |
| EPS Diluted
| -0.09 | 0.019 | 0.033 | 0.024 | -0.13 |
| EBITDA
| -17.115 | 3.833 | 7.689 | 15.366 | 4.035 |
| EBITDA Ratio
| -0.089 | 0.023 | 0.06 | 0.166 | 0.07 |